Completed PHASE2 INTERVENTIONAL 4-arm NCT02194023

Clinical Effects of Two New Chlorhexidine Digluconate Formulations: 0.12% and 0.03%.

Inhibition of de Novo Plaque Formation and Side Effects of Two New Mouthrinse Formulations: 0.12% and 0.03% Chlorhexidine Digluconate, Respectively, in a 4-day Non-brushing Model. A Triple-blind, Randomized Clinical Trial.

Sponsor: Dentaid SL

Conditions Dental Plaque Side Effects

Interventions 0.03%NF 0.12%NF PAT Placebo: PCB

Updated 7 times since 2017 Last updated: Jul 17, 2014 Started: Sep 30, 2011 Primary completion: Jul 31, 2013 Completion: Jul 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Dental Plaque and Side Effects and is currently completed. Dentaid SL leads this study, which shows 7 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Oct 2020 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Oct 2020 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dentaid SL
Universitat Internacional de Catalunya

Data source: Universitat Internacional de Catalunya

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Sant Cugat del Vallès, Spain